{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.426","value":"75.21"},{"groupId":"OG001","spread":"1.395","value":"77.28"}]}],"title":"At baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.430","value":"74.14"},{"groupId":"OG001","spread":"1.415","value":"76.71"}]}],"title":"At week 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.533","value":"73.72"},{"groupId":"OG001","spread":"1.498","value":"76.67"}]}],"title":"At week 16"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.644","value":"76.31"},{"groupId":"OG001","spread":"1.633","value":"77.98"}]}],"title":"At week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.903","value":"74.04"},{"groupId":"OG001","spread":"1.933","value":"75.64"}]}],"title":"At week 32"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.198","value":"76.58"},{"groupId":"OG001","spread":"2.388","value":"78.07"}]}],"title":"At week 40"}],"denoms":[{"counts":[{"groupId":"OG000","value":"566"},{"groupId":"OG001","value":"559"}],"units":"Participants"}],"description":"Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of functioning.","dispersionType":"Standard Error","groups":[{"description":"Cetuximab intravenous infusion of 400mg/m\\^2 for the first infusion then weekly intravenous infusion of 250mg/m\\^2. Bi-weekly Irinotecan infusion of 180mg/m\\^2, Folinic Acid infusion of 400mg/m\\^2 (racemic) or 200mg/m\\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\\^2 followed by a 46-hour continuous infusion of 2400mg/m\\^2 Number of Cycles: until progression or unacceptable toxicity develops","id":"OG000","title":"Cetuximab Plus FOLFIRI"},{"description":"Bi-weekly Irinotecan infusion of 180mg/m\\^2, Folinic Acid infusion of 400mg/m\\^2 (racemic) or 200mg/m\\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\\^2 followed by a 46-hour continuous infusion of 2400mg/m\\^2 Number of Cycles: until progression or unacceptable toxicity develops","id":"OG001","title":"FOLFIRI Alone"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"1125 subjects (566 in the Cetuximab + FOLFIRI arm and 559 in the FOLFIRI alone arm) completed at least one evaluable QLQ-C30 questionnaire and were thus included in the Evaluable for QLQ-C30 population","reportingStatus":"POSTED","timeFrame":"at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006","title":"Quality of Life Assessment (EORTC QLQ-C30) Social Functioning","type":"SECONDARY","unitOfMeasure":"scores on a scale"}